Loading…
H.R. 1414119th CongressIn committeeLatest action Feb 18, 2025Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
HR 1414 would double the tax credit for companies researching rare-disease drugs, from 25 cents to 50 cents per dollar spent.
35-second read · 4 questions answered below
This bill would raise the tax credit that pharmaceutical companies can claim for researching rare-disease drugs. The credit would go from 25 cents to 50 cents for every dollar spent on qualifying research and testing. The change would take effect in the first tax year after the bill becomes law.
Pharmaceutical companies that develop drugs for rare diseases would be directly affected by this change.
A higher tax credit makes it less costly for companies to research rare-disease drugs, which tend to reach very small numbers of patients. Developing these drugs can otherwise be unprofitable because so few people need them.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Referred to the House Committee on Ways and Means.